Browsing: Novo

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns…

For Novo Nordisk Philippines general manager Wei Sun, health isn’t a race to be won fast. It’s a lifelong partnership built on commitment and understanding

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets

Novo Nordisk A/SNVOreported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins

Novo Nordisk A/S (NOVO) held its Q2 2026 earnings call on August 5, 2026, during which the Phase III failure of ziltivekimab in cardiovascular outcomes dominated the R&D discussion, , while management defended CagriSema’s competitive positioning versus tirzepatide and the outlined the next wave of obesity assets led by zenagamtide

The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reaction underscored how sensitive investors are to clinical data, pipeline clarity, and competitive pressure from Eli Lilly’s obesity drugs. For you, this creates a chance to reassess exposure to companies tied…

Novo Nordisk’s CEO sought to reassure investors that its Wegovy pill can drive profitable growth despite lower prices, as investors sent the drugmaker’s shares lower following quarterly results

Novo CEO faces investor grilling after obesity drug disappointments | News24 Novo CEO faces investor grilling after obesity drug disappointments Share your Subscriber Article You have 5 articles to share every month. Send this story to a friend! Loading, please wait… 0:00Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one…

LONDON, Aug 3 – Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo